Market revenue in 2023 | USD 226.5 million |
Market revenue in 2030 | USD 300.2 million |
Growth rate | 4.1% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.74% in 2023. Horizon Databook has segmented the Sweden rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The Sweden rheumatoid arthritis therapeutics market is expected to be driven by healthcare reforms, research advancements, and patient-focused initiatives. With an increasing prevalence of RA due to an aging population, there is a growing need for effective and innovative treatment options in the country.
Healthcare reforms in Sweden aim to improve patient access to high-quality care and promote evidence-based treatments. These reforms encourage healthcare providers to adopt advanced RA therapies that offer better patient outcomes, leading to the exploration and implementation of new and innovative treatment modalities.
Research in the field of rheumatoid arthritis is also thriving in Sweden, focusing on developing biologic drugs and targeted therapies. These treatments aim to address the underlying causes of RA, providing more personalized and effective solutions for patients. The emphasis on R&D fosters innovation and improves RA care in Sweden.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Sweden rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account